Nicolas Ebel

2.2k total citations
7 papers, 206 citations indexed

About

Nicolas Ebel is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Nicolas Ebel has authored 7 papers receiving a total of 206 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Genetics. Recurrent topics in Nicolas Ebel's work include Cancer-related Molecular Pathways (2 papers), Chronic Myeloid Leukemia Treatments (2 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers). Nicolas Ebel is often cited by papers focused on Cancer-related Molecular Pathways (2 papers), Chronic Myeloid Leukemia Treatments (2 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers). Nicolas Ebel collaborates with scholars based in Switzerland, China and United States. Nicolas Ebel's co-authors include S. Sigrist, Masato Murakami, Thomas Radimerski, Vincent Romanet, M. Pinget, Rita Andraos, Fabienne Baffert, Nathalie Reix, Yves Frère and Remmelt Van der Werf and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Nicolas Ebel

7 papers receiving 205 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicolas Ebel Switzerland	6	110	71	51	47	37	7	206
Yunfeng Shen China	12	111 1.0×	96 1.4×	6 0.1×	101 2.1×	60 1.6×	29	309
Nundia Louis United States	8	149 1.4×	31 0.4×	8 0.2×	11 0.2×	44 1.2×	16	267
Yunwei Han China	8	71 0.6×	14 0.2×	13 0.3×	16 0.3×	61 1.6×	16	225
Linyi Liu China	14	191 1.7×	41 0.6×	4 0.1×	48 1.0×	72 1.9×	31	395
Noriko Konishi Japan	12	56 0.5×	25 0.4×	4 0.1×	63 1.3×	31 0.8×	27	317
Pengcheng Shi China	10	141 1.3×	37 0.5×	2 0.0×	107 2.3×	67 1.8×	35	320
Matthew Bedford United Kingdom	6	86 0.8×	52 0.7×	2 0.0×	88 1.9×	106 2.9×	13	280
Dongdong Luo China	11	219 2.0×	13 0.2×	9 0.2×	5 0.1×	121 3.3×	27	387
Tamara Fernández‐Marcelo Spain	11	174 1.6×	10 0.1×	7 0.1×	5 0.1×	78 2.1×	21	327
Wen-Tao Zhu China	10	257 2.3×	6 0.1×	35 0.7×	8 0.2×	52 1.4×	12	443

Countries citing papers authored by Nicolas Ebel

Since Specialization

Citations

This map shows the geographic impact of Nicolas Ebel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Ebel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Ebel more than expected).

Fields of papers citing papers by Nicolas Ebel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Ebel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Ebel. The network helps show where Nicolas Ebel may publish in the future.

Co-authorship network of co-authors of Nicolas Ebel

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Ebel. A scholar is included among the top collaborators of Nicolas Ebel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Ebel. Nicolas Ebel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Khera, Eshita, Dominik Hainzl, J. J. Davis, et al.. (2024). QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life. Journal of Pharmacokinetics and Pharmacodynamics. 52(1). 7–7. 3 indexed citations

2.

Fritsch, Christine, Estelle Pfister, Nicolas Ebel, et al.. (2018). Abstract 3934: Determination of the PI3Kα selective inhibitor alpelisib mechanism of action and efficacy in ER+/ PIK3CA mutant breast cancer preclinical models. Cancer Research. 78(13_Supplement). 3934–3934. 10 indexed citations

3.

Horn, Thomas, Stéphane Ferretti, Nicolas Ebel, et al.. (2016). High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. Cancer Research. 76(23). 6950–6963. 24 indexed citations

4.

Ebel, Nicolas, Vincent Romanet, Rita Andraos, et al.. (2013). JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease. Clinical Cancer Research. 19(22). 6230–6241. 59 indexed citations

5.

Reix, Nathalie, Audrey Parat, E. Seyfritz, et al.. (2012). In vitro uptake evaluation in Caco-2 cells and in vivo results in diabetic rats of insulin-loaded PLGA nanoparticles. International Journal of Pharmaceutics. 437(1-2). 213–220. 75 indexed citations

6.

Baffert, Fabienne, Nicolas Ebel, Rita Andraos, et al.. (2011). Improved Efficacy Upon Combined JAK1/2 and Pan-Deacetylase Inhibition Using Ruxolitinib (INC424) and Panobinostat (LBH589) in Preclinical Mouse Models of JAK2V617F-Driven Disease. Blood. 118(21). 798–798. 22 indexed citations

7.

Sigrist, S., Nicolas Ebel, A. Langlois, et al.. (2005). Role of Chemokine Signaling Pathways in Pancreatic Islet Rejection During Allo- and Xenotransplantation. Transplantation Proceedings. 37(8). 3516–3518. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact